title: Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health.
abstract: Metabolomics has emerged as an essential tool for studying metabolic processes, stratification of patients, as well as illuminating the fundamental metabolic alterations in disease onset, progression, or response to therapeutic intervention. Metabolomics materialized within the pharmaceutical industry as a standalone assay in toxicology and disease pathology and eventually evolved towards aiding in drug discovery and pre-clinical studies via supporting pharmacokinetic and pharmacodynamic characterization of a drug or a candidate. Recent progress in the field is illustrated by coining of the new term-Pharmacometabolomics. Integration of data from metabolomics with large-scale omics along with clinical, molecular, environmental and behavioral analysis has demonstrated the enhanced utility of deconstructing the complexity of health, disease, and pharmaceutical intervention(s), which further highlight it as an essential component of systems medicine. This review presents the current state and trend of metabolomics applications in pharmaceutical development, and highlights the importance and potential of clinical metabolomics as an essential part of multi-omics protocols that are directed towards shaping precision medicine and population health.
authors.affiliation: BERG, 500 Old Connecticut Path, Bldg. B, Framingham, MA 01701, USA. vladimir.tolstikov@berghealth.com.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Tolstikov
keywords: biomarkers; drug; mass spectrometry; metabolomics; patients; pharmaceutical